This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A: Frequency of DLTs
Timeframe: Up to 28 days
Parts A & B: Safety Evaluation of AZD0486
Timeframe: From signing of informed consent through data cutoff, up to 42 months
Parts B & C: Rate of CR within 3 cycles
Timeframe: Up to three cycles of 28 days each
AstraZeneca Clinical Study Information Center